Immune checkpoint blockade induced sarcoid-like reaction mimicking progression of disease in a patient with microsatellite instable colorectal cancer: case report and review of the literature

Journal of Gastrointestinal Oncology, Journal Year: 2024, Volume and Issue: 15(1), P. 500 - 507

Published: Feb. 1, 2024

Fergus Keane, Elizabeth Yogiaveetil, Brie Kezlarian, Maria Lagratta, Neil H. Segal, Ghassan Abou-Alfa, Eileen M. O’Reilly, Leonard Saltz, Imane El Dika

Language: Английский

---

Sarcoidosis-like reactions in metastatic renal cell carcinoma patients treated with immune-based combinations

Immunotherapy, Journal Year: 2024, Volume and Issue: 16(9), P. 603 - 609

Published: May 14, 2024

Aim: The incidence of drug-induced sarcoidosis-like reactions (DISR) in patients treated with immune checkpoint inhibitors (ICIs) is rising. We determine the and characteristics DISR a metastatic renal cell carcinoma (mRCC) population. Methods: retrospectively reviewed clinico-radiological data 83 mRCC at single institution immune-based combinations. Results: 15 received immune-doublet (ipilimumab–nivolumab), while 68 other Two cases (2.4%) were evidenced, enlargement mediastinal lymph nodes that mimicked disease progression, thus requiring biopsy which showed histological features DISR. Conclusion: In our series DISR, radiological clinical features, are line literature. diagnosis often only radiological, its occurrence possibly associated better outcome.

Language: Английский

---

Emerging Trends in Radionuclide Imaging of Infection and Inflammation in Pediatrics: Focus on FDG PET/CT and Immune Reactivity

Seminars in Nuclear Medicine, Journal Year: 2022, Volume and Issue: 53(1), P. 18 - 36

Published: Oct. 26, 2022

Language: Английский

---

Recommencement of atezolizumab with associated pulmonary sarcoid‐like reaction

Respirology Case Reports, Journal Year: 2024, Volume and Issue: 12(5)

Published: April 26, 2024

Abstract An 81 year old male with Child‐Pugh A cirrhosis and metastatic hepatocellular carcinoma (HCC) treated 3‐weekly atezolizumab bevacizumab developed a pulmonary sarcoid‐like reaction (SLR) after 5 months. Atezolizumab, an immune checkpoint inhibitor, was identified as the likely culprit. He prednisolone, resulting in improvement, successfully rechallenged both bevacizumab.

Language: Английский

---

Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors

Melanoma Research, Journal Year: 2023, Volume and Issue: unknown

Published: Oct. 13, 2023

Pembrolizumab and ipilimumab/nivolumab (ipi/nivo) combination are FDA-approved immune checkpoint inhibitor (ICI) therapies for metastatic melanoma. ICIs could result in various inflammation responses known as immune-related adverse events (IRAEs). We report a patient with melanoma who developed multiple IRAEs including sarcoidosis-like reaction (SLR), diabetic ketoacidosis (DKA), worsening hypothyroidism on ICIs. A 71-year-old man stage IIIC lymph node metastasis began adjuvant therapy pembrolizumab May 2021. surveillance positron emission tomography–computed tomography (PET-CT) scan four months later showed diffuse nodal uptake indicating potential metastases although the remained asymptomatic. His treatment was temporarily switched to ipi/nivo before biopsy obtained definitive diagnosis, which revealed non-caseating granulomas consistent SLR. After resuming pembrolizumab, he DKA November 2021, both of were attributed IRAEs. PET March 2022 again new hypermetabolic activity several bones, subcutaneous tissue, left inguinal node. Left disease recurrence, while biopsies nodules bone demonstrated granulomas. Our case described SLR is often asymptomatic but remains diagnostic challenge due its indistinguishable appearance imaging studies compared metastasis. Better understanding improved strategies needed optimal outcomes.

Language: Английский

---

Atypical and Typical Distant Sarcoid-like Reactions during Treatment of Metastatic Melanoma

Radiology Imaging Cancer, Journal Year: 2023, Volume and Issue: 5(2)

Published: March 1, 2023

Language: Английский

---